| 01/07/22 | 17:16:46 | 1 Jul 2022 | | Issue of Equity and Total Voting Rights |
| 30/06/22 | 07:15:05 | 30 Jun 2022 | | Duncan Tatton-Brown appointed as Non-Exec Chair |
| 23/06/22 | 16:30:00 | 23 Jun 2022 | | Result of AGM |
| 13/06/22 | 16:00:01 | 13 Jun 2022 | | Share Incentive Plan - Director/PDMR Shareholding |
| 01/06/22 | 16:00:01 | 1 Jun 2022 | | Issue of Equity and Total Voting Rights |
| 31/05/22 | 18:30:05 | 31 May 2022 | | Director/PDMR Shareholding |
| 26/05/22 | 07:00:11 | 26 May 2022 | | ONT releases Remora:most comprehensive methylation |
| 20/05/22 | 07:00:08 | 20 May 2022 | | Oxford Nanopore announces tech updates |
| 19/05/22 | 09:06:14 | 19 May 2022 | | ONT opens user conference, rich science programme |
| 13/05/22 | 07:00:04 | 13 May 2022 | | ONT chosen for comprehensive human genome program |
| 11/05/22 | 16:00:03 | 11 May 2022 | | Share Incentive Plan - Director/PDMR Shareholding |
| 03/05/22 | 16:00:02 | 3 May 2022 | | Issue of Equity and Total Voting Rights |
| 12/04/22 | 18:15:05 | 12 Apr 2022 | | Share Incentive Plan - Director/PDMR Shareholding |
| 12/04/22 | 13:01:06 | 12 Apr 2022 | | Director/PDMR Shareholding |
| 12/04/22 | 13:01:06 | 12 Apr 2022 | | Director/PDMR Shareholding |
| 12/04/22 | 13:00:05 | 12 Apr 2022 | | Director/PDMR Shareholding |
| 12/04/22 | 07:00:06 | 12 Apr 2022 | | Publication of Annual Report and Notice of AGM |
| 06/04/22 | 13:00:01 | 6 Apr 2022 | | Block listing Interim Review |
| 05/04/22 | 11:00:05 | 5 Apr 2022 | | Director/PDMR Shareholding |
| 04/04/22 | 14:00:02 | 4 Apr 2022 | | Genomics England expands Nanopore use in cancer |
| 01/04/22 | 17:00:06 | 1 Apr 2022 | | Issue of Equity and Total Voting Rights |
| 01/04/22 | 07:00:08 | 1 Apr 2022 | | Agreement |
| 30/03/22 | 14:00:01 | 30 Mar 2022 | | ONT shows new high-accuracy, high-output chemistry |
| 24/03/22 | 07:00:11 | 24 Mar 2022 | | Nanopore sequencing profiles TB: FIND evaluation |
| 23/03/22 | 14:02:32 | 23 Mar 2022 | | Oxford Nanopore releases Short Fragment Mode |
| 22/03/22 | 07:00:07 | 22 Mar 2022 | | Preliminary Results and Guidance Update |
| 11/03/22 | 17:00:01 | 11 Mar 2022 | | Share Incentive Plan - Director/PDMR Shareholding |
| 10/03/22 | 12:30:03 | 10 Mar 2022 | | Holding(s) in Company |
| 08/03/22 | 07:03:48 | 8 Mar 2022 | | Publication: Nanopore IDs >50 genetic diseases |
| 01/03/22 | 17:00:02 | 1 Mar 2022 | | Issue of Equity and Total Voting Rights |
| 24/02/22 | 07:00:12 | 24 Feb 2022 | | Notice of Results |
| 11/02/22 | 17:30:01 | 11 Feb 2022 | | Share Incentive Plan - Director/PDMR Shareholding |
| 01/02/22 | 17:00:07 | 1 Feb 2022 | | Issue of Equity and Total Voting Rights |
| 24/01/22 | 15:00:01 | 24 Jan 2022 | | Appointment of Senior Independent Director |
| 18/01/22 | 13:00:05 | 18 Jan 2022 | | Holding(s) in Company |
| 13/01/22 | 07:00:06 | 13 Jan 2022 | | Fastest human genome sequence uses Oxford Nanopore |
| 11/01/22 | 18:00:02 | 11 Jan 2022 | | Share Incentive Plan - Director/PDMR Shareholding |
| 07/01/22 | 12:00:02 | 7 Jan 2022 | | Update to FY21 revenue guidance |
| 07/01/22 | 07:00:07 | 7 Jan 2022 | | Company to present at JP Morgan Healthcare conf |
| 04/01/22 | 18:30:05 | 4 Jan 2022 | | Issue of Equity and Total Voting Rights |
| 20/12/21 | 17:00:02 | 20 Dec 2021 | | Holding(s) in Company |
| 13/12/21 | 18:15:08 | 13 Dec 2021 | | Share Incentive Plan - Director/PDMR Shareholding |
| 02/12/21 | 07:00:07 | 2 Dec 2021 | | Oxford Nanopore announces technology updates |
| 01/12/21 | 07:00:09 | 1 Dec 2021 | | Issue of Equity and Total Voting Rights |
| 09/11/21 | 07:03:40 | 9 Nov 2021 | | Update to revenue guidance |
| 03/11/21 | 18:00:02 | 3 Nov 2021 | | Holding(s) in Company |
| 01/11/21 | 18:30:02 | 1 Nov 2021 | | PDMR Notification (ESPP) and Director Declaration |
| 01/11/21 | 07:00:11 | 1 Nov 2021 | | Issue of Equity and Total Voting Rights |
| 14/10/21 | 17:33:00 | 14 Oct 2021 | | Upgrade to full-year revenue guidance |
| 13/10/21 | 18:20:00 | 13 Oct 2021 | | Share Incentive Plan, Director/PDMR Transactions |
